Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia

Several editions of the World Health Organization (WHO) classifications of lympho-hemopoietic neoplasms in 2001, 2008, and 2016 served as the international standard for diagnosis. Since the 4th WHO edition, here referred as WHO-HAEM4, significant clinico-pathological, immunophenotypic, and molecular advances have been made in the field of myeloid neoplasms, which have contributed to refine diagnostic criteria, to upgrade entities previously defined as provisional and to identify new entities. This process has resulted in two recent classification proposals of myeloid neoplasms: the International Consensus Classification (ICC) and the 5th edition of the WHO classification (WHO-HAEM5). In this paper, we review and compare the two classifications in terms of diagnostic criteria and entity definition, with a focus on adult myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia (AML). The goal is to provide a tool to facilitate the work of pathologists, hematologists and researchers involved in the diagnosis and treatment of these hematological malignancies.

Automated summary

The WHO classification of lympho-hemopoietic neoplasms in 2001, 2008, and 2016 has served as the international standard for diagnosis, but significant advancements have been made in myeloid neoplasms since the 4th WHO edition. This has led to the development of the International Consensus Classification (ICC) and the 5th edition of the WHO classification (WHO-HAEM5). This paper reviews and compares these two classifications, focusing on adult myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia (AML), with the aim of providing a useful tool for pathologists, hematologists, and researchers involved in the diagnosis and treatment of these hematological malignancies.